Annual Report 2024

• Zhuhai United Laboratories Co., Ltd. was ranked 23rd in the “2023 Top 100 Pharmaceutical Enterprises in China”. • The United Laboratories was awarded “ESG Comprehensive Governance Benchmarking Enterprise” in 2024 China International Fair for Trade in Services (CIFTS). SEPTEMBER • The marketing application of The United Laboratories for Insulin Degludec Injection was accepted by the National Medical Products Administration (“NMPA”). • The first subject of Phase IIa clinical study of TUL12101 Eye Drops, a Class 1 new drug, was enrolled in China. • The Amoxicillin Granules (specification: 0.125g) and Ceftazidime for Injection (specification: 1.0g) of The United Laboratories passed the consistency evaluation. • United Laboratories (Inner Mongolia) Ltd. and The United Animal Healthcare (Inner Mongolia) Co., Ltd. were selected as the “2024 Autonomous Region Champion Enterprises in Manufacturing Industry”. • The United Laboratories appeared at 20th CPHI Milan. OCTOBER • The Amoxicillin Sodium aseptic API of Zhuhai United Laboratories Co., Ltd. has once again received the CEP certificate issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). • The Cefuroxime Sodium for Injection (specifications: 0.75g, 1.5g) of The United Laboratories passed the consistency evaluation of quality and efficacy of generic drugs. • The United Laboratories was honored to be included in the “Top 50 Medium-sized Enterprises”, “Best Investment Value Award”, “Top 25 Pharmaceutical Companies” and “Top 50 in Hong Kong Stock Connect” lists in the 11th “Hong Kong Stocks Top 100”. • The United Laboratories was honored as one of the “2024 Top 10 Low-Carbon Pioneers of China’s Listed Pharmaceutical Companies in Response to Climate Change” by Healthcare Executive. NOVEMBER • Zhuhai United Laboratories Co., Ltd. was ranked 53rd in the “Top 500 Manufacturing Enterprises in Guangdong Province for 2024”. • The United Laboratories was honored as the “Most Valuable Pharmaceutical and Healthcare Company” in the 9th Selection of Listed Companies by Zhitongcaijing. • The marketing application of The United Laboratories for the Mupirocin Ointment (Specification: 2% (5g: 0.1g)) was approved by NMPA. • Zhuhai United Bio-Pharmacentical Co., Ltd. and its Liraglutide Injection, Insulin Degludec Injection and Semaglutide Injection were included in the first batch of segmented production enterprises and pilot varieties of biological products in Guangdong. DECEMBER CORPORATE CALENDAR OF 2024 3 The United Laboratories International Holdings Limited Annual Report 2024